BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA....
+See More2018-11-17 09:33:00 Saturday ET
Zillow share price plunges 20% year-to-date as its competitors Redfin and Trulia also experience an economic slowdown in the real estate market. The real es
2019-08-16 17:37:00 Friday ET
Amazon faces E.U. antitrust scrutiny over the current e-commerce use of merchant data. The European Commission probes into whether Amazon uses key third-par
2019-03-15 13:36:00 Friday ET
CNBC stock host Jim Cramer recommends both Caterpillar and Home Depot as the U.S. bull market is likely to continue in light of the recent Fed Chair comment
2022-02-05 09:26:00 Saturday ET
Modern themes and insights in behavioral finance Shiller, R.J. (2003). From efficient markets theory to behavioral finance. Journal of Economi
2025-06-20 08:27:00 Friday ET
President Trump poses new threats to Fed Chair monetary policy independence again. We describe, discuss, and delve into the mainstream reasons, conc
2022-11-30 09:26:00 Wednesday ET
Climate change and ESG woke capitalism In recent times, the Biden administration has signed into law a $375 billion program to better balance the economi